Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.1.1.28 (
lactic acid dehydrogenase
)
476
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An original experimental model has been presented for studying of cytoprotection of non-stimulated leukocytes. The model consists in determining of a degree of inhibition of the release of
lactic acid dehydrogenase
(
LDH
) by isolated human neutrophils (PMNs) in the course of their "ageing" at the room temperature (22 degrees C). Using this model for the first time, cytoprotective action was pointed-out of following compounds: NO (
EDRF
) in aqueous solution; natrium nitroprusside; active metabolite of molsidomine--SIN-1; N-acetyl-S-nitroso-penicillamine (SNAP) which are believed to owe their anti-platelet and vasodilatory activity to stimulation of cyclic-GMP--and iloprost (a stable prostacyclin analogue) and prostaglandin E2 (PGE2) which activate cyclic AMP. Effectiveness of cytoprotective action of these compounds increased as follows: NO (IC50 = 58.4) less than PGE2 (IC50 = 38) less than SIN-1 (IC50 = 9.2) less than SNAP (IC50 = 3.2) less than natrium nitroprusside (IC50 = 1.2) less than iloprost (IC50 = 0.2)(nmoles/5 x 10(6) PMNs; moreover, iloprost and SIN-1 showed a synergic action. Among ++nitroso-vasodilators, nitroglycerin had no cytoprotective action; it may indicate that to achieve cytoprotection in leukocytes a nitro- vasodilator should contain in its chemical structure -NO group and not -NO3 group, as it is in nitroglycerin. In neutrophils stimulated with calcium ionophore, arachidonic acid or FMLP, nitro-vasodilators are of no influence on production of superoxide anions O2-, hydroxyeicosatetraenoic acids (5-HETE and 12-HETE) and leukotriene B4. A hypothesis has been put forward on the relationship of function of c-GMP and c-AMP in the mechanism of cytoprotection of human leukocytes.
...
PMID:[Cytoprotective action of guanylate cyclase stimulators on human leukocytes]. 169 93